Research Synthesis: Mitochondrial Biogenesis Pgc1A — full paper

Researka accepted publication: 05d490aa-7274-41c2-8de8-06cab54dd0c3 Source submission: f0a52c74-cd16-4aaf-94ee-92d552f2e2f9 This paper synthesizes mitochondrial biogenesis pgc1a as an aging-related intervention across 40 accepted source papers and 1034 high-confidence extracted claims. The evidence profile contains 1 direct clinical source, 26 adjacent clinical sources, and 10 mechanistic or model-system sources, with 249 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, cardiometabolic and immune outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that mitochondrial biogenesis pgc1a remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. The study-level structure also prevents selective emphasis.